Literature DB >> 23649996

A novel multi-unit tablet for treating circadian rhythm diseases.

Qi Liu1, Yinhua Gong, Yun Shi, Liqun Jiang, Chunli Zheng, Liang Ge, Jianping Liu, Jiabi Zhu.   

Abstract

This study aimed to develop and evaluate a novel multi-unit tablet that combined a pellet with a sustained-release coating and a tablet with a pulsatile coating for the treatment of circadian rhythm diseases. The model drug, isosorbide-5-mononitrate, was sprayed on microcrystalline cellulose (MCC)-based pellets and coated with Eudragit(®) NE30D, which served as a sustained-release layer. The coated pellets were compressed with cushion agents (a mixture of MCC PH-200/ MCC KG-802/PC-10 at a ratio of 40:40:20) at a ratio of 4:6 using a single-punch tablet machine. An isolation layer of OpadryII, swellable layer of HPMC E5, and rupturable layer of Surelease(®) were applied using a conventional pan-coating process. Central-composite design-response surface methodology was used to investigate the influence of these coatings on the square of the difference between release times over a 4 h time period. Drug release studies were carried out on formulated pellets and tablets to investigate the release behaviors, and scanning electron microscopy (SEM) was used to monitor the pellets and tablets and their cross-sectional morphology. The experimental results indicated that this system had a pulsatile dissolution profile that included a lag period of 4 h and a sustained-release time of 4 h. Compared to currently marketed preparations, this tablet may provide better treatment options for circadian rhythm diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23649996      PMCID: PMC3666023          DOI: 10.1208/s12249-013-9975-8

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  17 in total

Review 1.  Modeling and comparison of dissolution profiles.

Authors:  P Costa; J M Sousa Lobo
Journal:  Eur J Pharm Sci       Date:  2001-05       Impact factor: 4.384

2.  A pulsatile drug delivery system based on rupturable coated hard gelatin capsules.

Authors:  T Bussemer; A Dashevsky; R Bodmeier
Journal:  J Control Release       Date:  2003-12-12       Impact factor: 9.776

Review 3.  Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery?

Authors:  Bi-Botti C Youan
Journal:  J Control Release       Date:  2004-08-27       Impact factor: 9.776

4.  Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.

Authors:  R Bonn
Journal:  Am J Cardiol       Date:  1988-03-25       Impact factor: 2.778

5.  Costs and clinical outcomes associated with use of ranolazine for treatment of angina.

Authors:  Charles E Phelps; Erin K Buysman; Gabriel Gomez Rey
Journal:  Clin Ther       Date:  2012-05-16       Impact factor: 3.393

6.  Mechanical properties of dry and wet cellulosic and acrylic films prepared from aqueous colloidal polymer dispersions used in the coating of solid dosage forms.

Authors:  R Bodmeier; O Paeratakul
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

7.  Nocturnal angina and sleep.

Authors:  G B Cassano; C Maggini; M Guazzelli
Journal:  Prog Neuropsychopharmacol       Date:  1981

8.  First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man.

Authors:  U Abshagen; S Spörl-Radun
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 9.  Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  W Schaumann
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-09

10.  Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology.

Authors:  Rajan K Verma; Aditya M Kaushal; Sanjay Garg
Journal:  Int J Pharm       Date:  2003-09-16       Impact factor: 5.875

View more
  2 in total

Review 1.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.

Authors:  Clara Hartmanshenn; Megerle Scherholz; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-19       Impact factor: 2.745

2.  A new design for a chronological release profile of etodolac from coated bilayer tablets: In-vitro and in-vivo assessment.

Authors:  Kirolos R Georgy; Ragwa M Farid; Randa Latif; Ehab R Bendas
Journal:  J Adv Res       Date:  2018-08-31       Impact factor: 10.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.